"For the first 38 years of my life, I was overweight - now I'm six stone (38kg) lighter," says Tanya
Gluckman, N
Figure 39: Photograph of Professor Matthias Tschp, 2017 credit: Astrid Eckert / TU Muenchen, Wikipedia
Your FTO, MC4R, GLP1R, and GIPR gene variants influence appetite regulation and medication response
Who This Cluster Is For People seeking long-term metabolic stability , not temporary appetite suppression Individuals using GLP-1 medications who want durable outcomes Anyone struggling with cravings, stress eating, or appetite swings Those with gut issues, inflammation, fatigue, or metabolic slowdown Readers looking for science-driven, microbiome-based insight How to Navigate This Cluster Start with Blog 1 understand GLP-1 biology Continue with Blogs 24 learn how diet, microbes, stress, and rhythms interact Finish with Blog 5 integrate everything into a complete metabolic blueprint Revisit as needed each article stands alone Why GLP-1 Outcomes Improve When the Microbiome Is Repaired GLP-1 medications suppress appetite, but they do not correct: dysbiosis impaired SCFA production circadian disruption gut-barrier inflammation stress-driven appetite loops When microbiome function is restored, GLP-1 sensitivity improves , SCFA pathways activate, cravings stabilize, and metabolic flexibility returns
Soon, Adrian was mixing up his own tirzepatide at home, going to great lengths to thoroughly test the powdered form of the drug he ordered from China for heavy metals and other toxins
